Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Misato Hashizume

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Plos One|December 25, 2015
Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)Keisuke Izumi, Yuko Kaneko, Misato Hashizume, et al.
Arthritis Research & Therapy|January 22, 2015
Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical responseJun Kikuchi, Misato Hashizume, Yuko Kaneko, et al.
Journal of Translational Medicine|June 9, 2018
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexateAlison O'Mahony, Markus R John, Hannah Cho, et al.
Clinical and Experimental Immunology|September 14, 2013
Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis modelKeisuke Tanaka, Misato Hashizume, Masahiko Mihara, et al.
Arthritis Research & Therapy|May 2, 2012
Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis modelMisato Hashizume, Hiroto Yoshida, Keisuke Tanaka, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2010
Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytesTomomi Furihata, Yukina Fukuchi, Minami Iikura, et al.
Nature Reviews. Rheumatology|April 25, 2020
Translating IL-6 biology into effective treatmentsErnest H Choy, Fabrizio De Benedetti, Tsutomu Takeuchi, et al.
International Reviews of Immunology|August 8, 2014
Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insightsMisato Hashizume, Seng-Lai Tan, Junichi Takano, et al.
Modern Rheumatology|October 21, 2025
Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor antibody, in 342 Japanese patients with multicentric Castleman disease: a 3-year, prospective, observational studyNorihiro Nishimoto, Miho Murakami, Takeshi Johkoh, et al.
JCI Insight|July 21, 2017
Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHDLudovic Belle, Vivian Zhou, Kara L Stuhr, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Plos One|December 25, 2015
Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study)Keisuke Izumi, Yuko Kaneko, Misato Hashizume, et al.
Arthritis Research & Therapy|January 22, 2015
Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical responseJun Kikuchi, Misato Hashizume, Yuko Kaneko, et al.
Journal of Translational Medicine|June 9, 2018
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexateAlison O'Mahony, Markus R John, Hannah Cho, et al.
Clinical and Experimental Immunology|September 14, 2013
Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis modelKeisuke Tanaka, Misato Hashizume, Masahiko Mihara, et al.
Arthritis Research & Therapy|May 2, 2012
Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis modelMisato Hashizume, Hiroto Yoshida, Keisuke Tanaka, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2010
Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytesTomomi Furihata, Yukina Fukuchi, Minami Iikura, et al.
Nature Reviews. Rheumatology|April 25, 2020
Translating IL-6 biology into effective treatmentsErnest H Choy, Fabrizio De Benedetti, Tsutomu Takeuchi, et al.
International Reviews of Immunology|August 8, 2014
Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insightsMisato Hashizume, Seng-Lai Tan, Junichi Takano, et al.
Modern Rheumatology|October 21, 2025
Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor antibody, in 342 Japanese patients with multicentric Castleman disease: a 3-year, prospective, observational studyNorihiro Nishimoto, Miho Murakami, Takeshi Johkoh, et al.
JCI Insight|July 21, 2017
Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHDLudovic Belle, Vivian Zhou, Kara L Stuhr, et al.
Pageof 4